284
Participants
Start Date
February 28, 2015
Primary Completion Date
January 31, 2018
Study Completion Date
May 31, 2018
Moxifloxacin
Oral
PA-824
Oral
Pyrazinamide
Oral
HRZE (Rifampicin, Isoniazid, Pyrazinamide, Ethambutol combination)
Oral
HR (rifampicin plus isoniazid combination tablets)
Oral
Philippine General Hospital, Ermita
Lung Center of Philippines, Manila
Vincent Balang, Pio del Pilar
The Aurum Institute: Tembisa Hospital Cnr, Tembisa
Klerksdorp Tshepong Hospital, Klerksdorp
Durban International Clinical Trials Unit (DbnlCTU), Durban
THINK: Tuberculosis & HIV Investigative Network of Kwazulu Natal, Durban
TASK, Bellville
University of Cape Town Lung Institute, Mowbray
Institute of Respiratory Medicine (IPR), Kuala Lumpur
National Center for Tuberculosis and Lung Diseases, Tbilisi
Centre for Respiratory Disease Research (CRDR) Keny Medical Research Institute (KEMRI), Nairobi
Centre for Respiratory Disease Research (CRDR) Kenya Medical Research Institute (KEMRI), Nairobi
Pusat Perubatan Universiti Kebangsaan, Cheras
Universiti Teknologi MARA, Batu Caves
Setshaba Research Centre, Pretoria
CHRU Themba Lethu Clinic, Westdene
Synexus SA, Mamelodi East
The Aurum Institute, Klerksdorp
The Aurum Institute: Rustenberg, Rustenburg
Ifakara Health Institute (IHI), Dar es Salaam
NIMR - Mbeya Medical Research Programme (MMRP), Mbeya
Kilimanjaro National Institute for Medical Research, Mwanza
Uganda CWRU Research Collaboration, Kampala
Centre for Infectious Disease Research in Zambia (CIDRZ), Lusaka
Madibeng Centre for Research (MCR), Brits
Global Alliance for TB Drug Development
OTHER